BioSpace News Archive

Drug Development

Momotaro-Gene Announces First Patient Dosed in Phase 2 Clinical Trial of MTG201 in Combination with Nivolumab in Patients with Relapsed Malignant Pleural Mesothelioma

Combination of Novel Gene Therapy and Immunotherapy Being Evaluated for Synergistic Anti-Tumor Activity in Patients with Cancer with Limited Treatment Options

September 12, 2019
·
5 min read
Business

Orion Pharmaceuticals Implements Genedata Biologics to Support New Large-Molecule R&D Initiative

Genedata Biologics to accelerate antibody discovery and streamline R&D operations at Finland’s largest biopharma company

September 12, 2019
·
3 min read
Drug Development

Genentech’s Satralizumab Shows Strong Results in Rare CNS Disorder

The company presented the data at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.

September 12, 2019
·
2 min read
·
Mark Terry
Sequana Medical to attend upcoming scientific conferences

Sequana Medical NV announces that it will be attending the following upcoming scientific conferences

September 12, 2019
·
4 min read
Policy

Purdue Reaches Tentative $12 Billion Settlement, But Some Opposition Remains

Purdue Pharmaceuticals has reached a tentative settlement in thousands of opioid cases that could cost the company about $12 billion, but some litigation against the firm is expected to continue over its role in the opioid crisis.

September 12, 2019
·
2 min read
·
Alex Keown
Business

QuantuMDx Group appoints Neil Butler as a Non-Executive Director

QuantuMDx Group appoints Neil Butler as a Non-Executive Director

September 12, 2019
·
2 min read
Deals

Ermium Therapeutics completes Series A funding of €6.3 million to develop breakthrough auto-immune therapeutics

Ermium Therapeutics announced a series A funding of €6.3 M with Domain Therapeutics, Kurma Partners, Idinvest, and the SATT Erganeo.

September 12, 2019
·
4 min read
Deals

Primer Capital has invested in the development of a drug that eliminates the consequences of neurodegenerative diseases

The startup’s unique technology allows to halt the development of the short memory impairment that is characteristic of the patients with various neurodegenerative diseases.

September 12, 2019
·
2 min read
Policy

Auris Medical Announces Notices of Allowance for U.S. and European Patent Applications Covering Intranasal Betahistine

Received Notice of Allowance from United States Patent and Trademark Office -- Received “Intention to Grant” notice from European Patent Office

September 12, 2019
·
5 min read
Business

IBA signs contract to install a Cyclone® 70 system in South Africa

Cyclotron to be dedicated to the production of radiopharmaceuticals for diagnosing and treating critical illnesses worldwide

September 12, 2019
·
3 min read